Share

September 2019; 6 (5) ArticleOpen Access

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD

Lawrence J. Cook, John W. Rose, Jessica S. Alvey, Anna Marie Jolley, Renee Kuhn, Brie Marron, Melissa Pederson, Rene Enriquez, Jeff Yearley, Stephen McKechnie, May H. Han, Anna J. Tomczak, Michael Levy, Maureen A. Mealy, Jessica Coleman, Jeffrey L. Bennett, Ruth Johnson, Myka Barnes-Garcia, Anthony L. Traboulsee, Robert L. Carruthers, Lisa Eunyoung Lee, Julia J. Schubert, Katrina McMullen, Ilya Kister, Zoe Rimler, Allyson Reid, Nancy L. Sicotte, Sarah M. Planchon, Jeffrey A. Cohen, Diane Ivancic, Jennifer L. Sedlak, Ilana Katz Sand, Pavle Repovic, Lilyana Amezcua, Ana Pruitt, Erika Amundson, Tanuja Chitnis, Devin S. Mullin, Eric C. Klawiter, Andrew W. Russo, Claire S. Riley, Kaho B. Onomichi, Libby Levine, Katherine E. Nelson, Nancy M. Nealon, Casey Engel, Mason Kruse-Hoyer, Melanie Marcille, Leticia Tornes, Anne Rumpf, Angela Greer, Megan Kenneally Behne, Renee R. Rodriguez, Daniel W. Behne, Derek W. Blackway, Brian Coords, Terrence F. Blaschke, Judy Sheard, Terry J. Smith, Jacinta M. Behne, Michael R. Yeaman, on behalf of The Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF–ICC)
First published June 28, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000583
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
752

Share

Abstract

Objective To develop a resource of systematically collected, longitudinal clinical data and biospecimens for assisting in the investigation into neuromyelitis optica spectrum disorder (NMOSD) epidemiology, pathogenesis, and treatment.

Methods To illustrate its research-enabling purpose, epidemiologic patterns and disease phenotypes were assessed among enrolled subjects, including age at disease onset, annualized relapse rate (ARR), and time between the first and second attacks.

Results As of December 2017, the Collaborative International Research in Clinical and Longitudinal Experience Study (CIRCLES) had enrolled more than 1,000 participants, of whom 77.5% of the NMOSD cases and 71.7% of the controls continue in active follow-up. Consanguineous relatives of patients with NMOSD represented 43.6% of the control cohort. Of the 599 active cases with complete data, 84% were female, and 76% were anti-AQP4 seropositive. The majority were white/Caucasian (52.6%), whereas blacks/African Americans accounted for 23.5%, Hispanics/Latinos 12.4%, and Asians accounted for 9.0%. The median age at disease onset was 38.4 years, with a median ARR of 0.5. Seropositive cases were older at disease onset, more likely to be black/African American or Hispanic/Latino, and more likely to be female.

Conclusions Collectively, the CIRCLES experience to date demonstrates this study to be a useful and readily accessible resource to facilitate accelerating solutions for patients with NMOSD.

Glossary

AQP4=
aquaporin-4;
ARR=
annual relapse rate;
CRC=
Clinical Research Coordinator;
EDSS=
Expanded Disability Status Scale;
GJCF=
The Guthy-Jackson Charitable Foundation;
ICC=
International Clinical Consortium;
IQR=
interquartile range;
MOG=
myelin oligodendrocyte glycoprotein;
NMOSD=
neuromyelitis optica spectrum disorder;
PSF=
patient study file

Neuromyelitis optica spectrum disorder (NMOSD) represents a chronic, potentially debilitating and life-threatening neuroinflammatory process primarily targeting the optic nerves, spinal cord, and brain.1,–,4 The typical clinical course of NMOSD is marked by multiple relapses resulting in cumulative neurologic disabilities. These events are interspersed with remissions from disease activity of variable duration. Heightened awareness of the disease among health care providers and the public and recent advances in diagnostic precision have increased estimates of worldwide NMOSD prevalence, reaching as high as 10 per 100,000 in some populations.5,–,8 This projection translates to more than 15,000 patients with NMOSD in the United States, suggesting that hundreds of thousands of cases exist worldwide. NMOSD disproportionately affects females (up to 7:1 female-to-male ratio), with anti-aquaporin-4 (AQP4) antibody (hereafter referred to as anti-AQP4) positive disease having even greater propensity for women.9,10 Yet, many details regarding etiology, pathogenesis, risk factors, and demography of NMOSD are in need of greater understanding.

Although case series and observational studies suggest benefit from immunotherapy, to date no treatment of NMOSD has been proven safe and effective in prospective, double-masked and adequately powered clinical trials.11,–,13 Because of its rarity, insufficient access to well-characterized patient cohorts has historically hindered studies as has an absence of high-fidelity preclinical models of human disease. Limitations in carefully standardized, longitudinal clinical research tools have also impeded investigation of NMOSD immunopathogenesis. However, 4 separate clinical trials have now reported positive results evaluating 3 compounds (eculizumab, satralizumab, and inebilizumab) in studies assessing efficacy in delaying or preventing relapses in NMOSD.

The Guthy-Jackson Charitable Foundation (GJCF) initiated an observational study of NMOSD in which patients and comparative controls are enrolled and evaluated longitudinally in a standardized manner. This study, known as Collaborative International Research in Clinical and Longitudinal Experience Studies (CIRCLES) for NMOSD, was launched in November 2013. In CIRCLES, participant clinical data, demographic profiles, and biospecimens were collected at geographically dispersed academic medical centers located throughout North America (figure 1).

Figure 1
Figure 1 Geographic location of CIRCLES clinical sites

The design and performance of the CIRCLES study are described here, along with initial data analysis illustrating the utility of its database and biorepository to advance scientific knowledge and clinical care in NMOSD. It is anticipated that this study will accelerate greater understanding of NMOSD and in turn the development of safe and effective therapies to benefit patients with NMOSD and perhaps those diagnosed with other autoimmune diseases.

Methods

Clinical research standards

Human subjects protection

Participant enrollment is conducted in accordance with the guidelines specified by the Office of Human Research Protections of the US Food and Drug Administration. A standardized protocol, manual of operations, patient study file (PSF), and informed consent or assent documents were approved by the institutional review board of each participating institution. Written and verbal consent or assent was obtained before beginning study procedures. The protocol and PSF were updated periodically.

Study goals and design

Design

CIRCLES is a prospective, multicenter, cross-sectional, and longitudinal study enabling comparisons of NMOSD cases and controls from which clinical data and biospecimens were collected using standardized methods. These were collected from cases at 6-month intervals and at least annually from control participants. When possible, clinical data and biospecimens were obtained from cases during or within 10 days following clinically confirmed relapses.

Goals

Two primary goals of CIRCLES include the following: (1) establish a cohort of patients with NMOSD and comparative controls who are longitudinally assessed at standardized intervals and (2) analyze acquired clinical data and biospecimens, thus improving knowledge of NMOSD and the patient experience.

Sites

Multiple study sites were established at academic institutions throughout North America (figure 1), each led by a clinical investigator/neurologist with expertise in NMOSD. Study sites were selected based on the size/activity of their NMOSD patient cohort and capability to collect data and biospecimens in the protocol-defined manner. Biospecimens, predominantly peripheral blood constituents, are rapidly transferred to a centralized commercial laboratory for processing and archiving.

Cohorts

The study comprises 3 participant cohorts based on the following inclusion criteria: (1) cases with clinically diagnosed NMOSD according to either the Wingerchuk 200614 or International Panel for NMOSD Diagnosis 201514 criteria and classified with respect to anti-AQP4 serostatus; (2) comparative disease controls (including CNS autoimmune diseases [e.g., MS]; other autoimmune diseases [e.g., systemic lupus erythematosus, Sjögren syndrome, and type I diabetes mellitus]; chronic nonautoimmune inflammatory or systemic conditions [e.g., cardiovascular disease and type 2 diabetes]); and (3) healthy controls (i.e., those not carrying a chronic disease diagnosis at enrollment). Controls included consanguineous relatives and unrelated individuals (tables 1 and 2). Enrollment is targeted to a 2:1 ratio of cases to controls and is monitored centrally. Individuals (both cases and controls) are excluded if the treating physician feels that they are not appropriate for the study. Control participants are not sex or age matched. Some comparative disease controls are recruited from referral cohorts (e.g., MS). Others are recruited through opportunity or convenience. Sites are instructed to enroll control participants at a rate of 50% MS and 50% from the other categories.

View this table:
Table 1

Summary of case participant characteristics by serostatus

View this table:
Table 2

Summary of control participant characteristics by relatedness to NMOSD cases

Intervals

After enrollment, NMOSD cases are evaluated clinically at 6-month intervals to provide an updated clinical history and complete set of biospecimens. Control participants undergo these same assessments at least annually. The panel of biospecimens routinely collected is listed in supplemental table 1 (links.lww.com/NXI/A121). The protocol allows collection of CSF and additional tissues (e.g., placenta) as available from medically indicated care. Relapses are evaluated regardless of interval and adjudicated by site neurologists.

Participating cohorts

Eligibility

Individuals fulfilling inclusion criteria and absent exclusion criteria are eligible for enrollment. Individuals weighing <17 kg are excluded from blood collections but may otherwise participate.

Enrollment

Clinical research coordinators (CRCs) screen information pertaining to inclusion and exclusion criteria. Individuals receive study information through mail and/or social media and, where institutional review board-approved, have the option to provide preliminary information telephonically with consent obtained in advance of study participation. At enrollment, a thorough review of medical records and clinical examination is performed by the study neurologist. A complete disease history and additional relevant study data are collected during the initial interview (table e-3, links.lww.com/NXI/A121). The majority of participants to date have been enrolled coinciding with medically indicated appointments; however, in some cases, enrollment was conducted per protocol at patient-oriented educational events.

Clinical database

Clinical metadata

The CIRCLES PSF (table e-2, links.lww.com/NXI/A121) is completed for each participant at enrollment and updated at each follow-up study visit. The PSF data include demographics, disease phenotype, treatment history, and other relevant characteristics. Other than NMOSD disease history, identical clinical data are collected as appropriate from case and healthy control participants.

Data security

Data are entered into a web-accessible and password-secured electronic data capture system. The CIRCLES study incorporates a query management system that executes nightly. An email notification is generated for each site's CRC identifying any new discrepant data. A weekly reminder email is also provided for remaining discrepant data. The system tracks queries from generation to resolution. Data are curated for quality, consistency, and completeness by the Data Coordinating Center biostatistics group before archiving. Study data are backed up hourly, and a full snapshot of the study is archived nightly.

Biospecimen repository

Collection, processing, and storage

Biospecimens are collected according to standard operating procedures at enrollment and follow-up visits. A panel of blood specimens is obtained (table e-1, links.lww.com/NXI/A121) by routine venipuncture by a certified phlebotomist at each scheduled clinical visit. Biospecimens are transported by express courier to a commercial laboratory for processing, systematic labeling, and archiving within 24 hours of collection under certified storage conditions (liquid nitrogen for peripheral blood mononuclear cells and −80°C for sera, plasma, RNA, and DNA).

Quality and serostatus

Biospecimens are routinely assessed for quality postprocessing and before cryopreservation. Autoantibody serostatus is determined by the respective study site based on reference laboratory assay or review of the case record. For analytical purposes, seropositivity is defined as having detected anti-AQP4 at any point during the participant's history.

Statistical analysis

Analytical range

The current report encompasses data sets obtained from 2013 through 2017. The CIRCLES study is ongoing.

Analytical methods

Descriptive statistics (medians or interquartile ranges [IQRs] for numeric variables; counts and percentages for categorical variables) were used to analyze data. Wilcoxon rank-sum tests were used to assess relationships between age at disease onset, annualized relapse rate (ARR) during enrollment in the study, and time between the first and second attacks in relation to other demographic characteristics in NMOSD cases. Relationships between serostatus and race, serostatus and sex, and race and sex were examined using χ2 tests. All analyses were performed in SAS 9.4 (Cary, NC).

Data availability

Access to data and biospecimens is provided to qualified scholars in a peer-reviewed process. Applications are adjudicated by a biorepository oversight committee elected from among the members of the GJCF International Clinical Consortium (ICC).

Results

Study enrollment

As of December 2017, CIRCLES had enrolled 849 NMOSD cases and 339 controls, of which 658 (77.5%) and 243 (71.7%), respectively, continue to participate. The percentage of enrollees remaining active has increased over time. Of the 161 participants enrolled in 2013, 49.7% are still active. This compares to 73.7% of those enrolled in 2014, 67.9% in 2015, 74.4% in 2016, and 90.8% in 2017. Inability to contact accounted for most inactivity (74%), followed by withdraw of consent (14%), no longer able to participate (9%), and death (2%). Of all participants, 60.3%, 31.3%, and 8.4% were enrolled at study sites, national patient day events, and regional patient day events, respectively. In-clinic enrollees, compared with national and regional patient day enrollees, were more likely to remain active (89.7% vs 55.1% and 74.5%, respectively). The size of the enrolled cohort varied among study sites, with the largest site enrolling 286 (24.1%) of all participants and the smallest enrolling 20 (1.7%). Among active NMOSD cases, 495 (75.2%) have undergone one or more follow-up visits with biospecimen collection. Among active controls, 129 (53.1%) had one or more follow-up visits and biospecimen collection. The remainder of the analyses presented are based on these active cases and control participants who have complete data as of the end of the study period.

Cohort demographics and epidemiology

In the CIRCLES cohort, the female-to-male ratio was 5.3:1 among cases (tables 1 and 2). NMOSD cases self-identified as white/Caucasian (52.6%), 23.5% black/African American, 12.4% Hispanic/Latino, 9.0% Asian, and 2.5% from all other races/ethnicities. The overall median age at NMOSD onset was 38.4 years (IQR 28.9–50.6 years), appears to be normally distributed, and spans the range from 2.7 to 79.9 years (figure 2). The median time between disease onset and time to study enrollment was 4.6 years (IQR 1.5–10.1 years). CIRCLES cases experienced an ARR of 0.5 (IQR 0.3–0.9). One hundred thirty-two cases appear to be monophasic. For cases with ≥2 clinically documented NMOSD relapses (n = 207), the median time between the first and second attacks was 0.8 years (9 months; IQR 3.3–27.9). The most common relapse manifestations were longitudinally extensive transverse myelitis (≥2 vertebral segments; 396, 66.1%) and optic neuritis (395, 65.9%). Brainstem syndromes were identified in 155 (25.9%) cases, 143 (23.9%) manifested focally confined transverse myelitis, 88 (14.7%) area postrema syndrome (e.g., prolonged or intractable nausea/vomiting or hiccups), 74 (12.4%) cerebral syndrome (cognitive and/or sensory impairment, pain, bowel and/or bladder dysfunction, or limb weakness), and 23 (3.8%) diencephalic and/or brainstem syndromes (facial numbness, hearing loss, dysphagia, or dysarthria) (table 1).

Figure 2
Figure 2 Age at onset by serostatus and gender

Biospecimen repertoire

Of the active NMOSD cases, 193 (32.2%) provided a single set of biospecimens; 2 longitudinal sets were collected from 151 (25.2%) cases, 3 sets from 107 (17.9%), and 4 or more from 131 (21.9%). Of the active controls, 102 (46.8%) provided a single biospecimen set, 65 (29.8%) 2 sets, 26 (11.9%) 3 sets, and 21 individuals (9.6%) have provided 4 or more longitudinal samples.

Correlation analyses

Bioinformatic analyses have revealed several significant correlates in the CIRCLES cohort (table 1). Anti-AQP4 seropositive cases were more likely to be female (87.5%) compared with seronegative cases (73.4%, p < 0.001). Significant differences in racial distribution by serostatus (p < 0.001) were also detected. This result was driven largely by differences in the black/African American and white race categories. Although black/African American participants accounted for only 11.5% of the seronegative population, they comprise 27.8% of seropositive cases. Similarly, Hispanic/Latino cases represent only 9.4% of seronegative cases, but 13.4% of seropositive cases. Conversely, white/Caucasian cases account for 62.6% of seronegative cases, but less than half (48.6%) of the seropositive cases. Similarly, Asians account for a higher percentage of the seronegative population (12.2%) compared with the seropositive population (8.2%).

Overall, seropositive cases are older at initial NMOSD attack compared with seronegative participants (39.4 vs 35.1; p = 0.002; figure 2). White/Caucasian and Asian cases tend to be older at first attack compared with black/African Americans or Hispanics (41.1 and 38.3 vs 36.5 and 36.0, p < 0.001; table 3). Seropositive cases tend to have lower ARR than those who are seronegative (0.46 vs 0.55; p = 0.030). No significant differences were detected between race and ARR (p = 0.34).

Of the 218 control participants, 95 (43.6%) are consanguineous with an enrolled case. One hundred forty-four (66.1%) are female. The median age of controls at enrollment was 47.1 years. Of the related controls, none have MS, 17.9% have another autoimmune disease, and 82.1% have no comparative disease or chronic condition. Of the unrelated controls, 28.5% have MS, 15.4% have another autoimmune disease, and 56.1% have no comparative disease or condition (table 2).

Discussion

The CIRCLES study represents a unique and multicenter longitudinal observational study, which has successfully recruited and retained a large number of patients affected by the rare disease NMOSD. The substantial number of control participants who are consanguineous with enrolled cases also provides important new opportunities to understand disease resilience. In this respect, individuals with familial genotypes and environmental exposures, but who do not manifest NMOSD, can be evaluated in relation to patients with NMOSD. In addition, the CIRCLES project reflects the collaborative input of the GJCF-ICC, a global network of scientific and medical experts in NMOSD.

The demographic characteristics of the CIRCLES cohort to date are comparable to those of previously described NMOSD registries.13,15,–,22 Interesting relationships have emerged from initial demographic, epidemiologic, and correlational analyses of this cohort. Key relationships include identification of correlations between disease attributes and sex, age, and race. NMOSD cases are predominantly female (5.3:1) and anti-AQP4 seropositive (76.4%). Disease onset most commonly occurs in the fourth decade of life. These findings are congruent with recent epidemiologic studies of NMOSD regarding sex predominance, age at onset, and disease clustering in individuals and their first-degree relatives.5,23,–,25

View this table:
Table 3

Case demographic factors by race and ethnicity

Analysis of the CIRCLES cohort supports the concept that a sizable proportion of cases satisfying either 2006 or 2015 diagnostic criteria for NMOSD14,26 includes individuals in whom anti-AQP4 is not detected. Approximately 20.6% of female and 39.8% of male cases in CIRCLES are anti-AQP4 seronegative, representing a significant difference based on sex (p < 0.001). Whether such proportions accurately reflect anti-AQP4 serostatus worldwide, correlate with specific disease phenotypes, or inform regarding response to therapy remains uncertain. Key among the proximate determinants of this serostatus are anti-AQP4 assay sensitivities and specificities. For example, it is possible that therapies inadvertently affect selection bias (e.g., rituximab targeting B cells). However, no consistent evidence published to date has proven these therapies alter antibody detection in Clinical Laboratory Improvement Amendments–approved assays. Seropositive cases are more likely to be female, and self-identified black/African American or Hispanic/Latino patients are more likely to be anti-AQP4 seropositive, congruent with earlier reports.5 Furthermore, cases in which anti-AQP4 is detected are older at first attack than those who are seronegative (39.4 vs 35.1, respectively, p = 0.002). Although white/Caucasian cases accounted for nearly 63% of the anti-AQP4 seronegative cohort, they account for less than 50% of seropositive cases. The age at first attack also differed by race, with a nearly 5-year disparity between the median age at onset for Hispanics/Latinos compared with white/Caucasians. This finding could reflect socioeconomic skewing of access to specialized medical care, a difference in disease activity/severity, other factor(s), or a combination of factors.

Of note, the prevalence of NMOSD appears to differ in distinct geographic regions. For example, the current estimate of NMOSD prevalence is 3.9 per 100,000 in Olmsted County, Minnesota (USA),5 similar to that reported in Denmark (4 per 100,00027). In contrast, the prevalence ranges from 0.72 per 100,000 in England,28 0.89 per 100,000 in Spain,7 and 0.9 per 100,000 in Japan6 to 1.96 per 100,000 in Wales,29 2.5 per 100,000 in the French West Indies,30 2.6 per 100,000 in India,31 and as high as 10 per 100,000 in Martinique.5 It is possible that differences in diagnostic criteria could underlie at least some of these apparent differences. In any event, the current CIRCLES data offer insights extending those provided by recent reviews.8,32

The sizable proportion of cases in which anti-AQP4 is not detected suggests that the NMOSD phenotype can result from multiple, independent immunologic events. The emerging recognition of individuals with phenotypes resembling NMOSD, but in whom anti-myelin oligodendrocyte glycoprotein (anti-MOG) autoantibodies are detected in the absence of anti-AQP4,10,33,34 suggests at least 2 intriguing possibilities: (1) a broader array of autoantigens than traditionally appreciated may contribute to astrocytopathies and/or (2) patients having anti-MOG autoantibodies may reflect a disease entity that is immunologically distinct from NMOSD, despite largely superimposable clinical manifestations. Thus, patients with anti-MOG antibodies may exhibit disease features that are pathogenically distinct from NMOSD, despite their similar clinical presentations.34,35 Nevertheless, 1 recent epidemiologic study showed that individuals with detectable anti-MOG antibody had similar disease prevalence and long-term prognosis when compared with patients lacking detectable anti-AQP4 or anti-MOG antibody.10 Thus, the relationship between serology and disease phenotype remains to be more clearly understood.

As with all large, multicenter clinical research studies, there are limitations to CIRCLES. Some participants inconsistently followed up or provided incomplete historical information. Complete acquisition of PSF data elements, biospecimens, and fully documented neurologic examination data has proven challenging. In turn, acquiring disability data from incomplete neurologic examinations has emerged as a high priority for improvement. For example, although 90.9% of examinations included completed motor function assessments, only 49.5% assessed visual acuity, and 8.7% completed the Expanded Disability Status Scale. The study has not systematically monitored anti-MOG serostatus,16 as no approved clinical assay for this autoantibody existed during the study period.

A unique aspect of CIRCLES concerns the detailed clinical history captured at enrollment. For those whose disease is of long duration, recall bias is possible. Beyond basic clinical data, the CIRCLES PSF requests extensive retrospective clinical information, including history of infectious diseases, vaccinations, familial autoimmune diseases, medications, and treatments. Although collection of such extensive information is labor intensive, the resulting data set enables interrogations not possible from smaller or less comprehensive databases. Opportunities for enhancing study performance are currently being addressed through refinements of the study protocol. In particular, increased emphasis has been placed on longitudinal participation, more frequent site monitoring, and systematic methods for disseminating information to study sites pertaining to study performance and efficiency.

The design of CIRCLES allows direct comparisons between the clinical courses of NMOSD and other autoimmune diseases, informing key immunologic events unique to NMOSD. These events in turn facilitate identification of clinically useful biomarkers, including those heralding disease relapse, as well as novel therapeutic targets, agents, and strategies. The CIRCLES biobank contains clinical information and biospecimens from ethnically and geographically diverse cases, including those with heterotypic phenotypes. Thus, CIRCLES represents a unique resource to the academic and drug-discovery communities focused on finding solutions for patients with NMOSD and may enhance parallel efforts in other immune-based diseases.

In summary, areas of research urgently needed in NMOSD include discovery of disease etiology, identification of risk factors, and identification of biomarkers reflecting disease activity and predicting relapse.36,37 The ongoing CIRCLES continues to enroll and follow cases and categorical control participants in a systematic and longitudinal manner. This effort is intended to facilitate breakthroughs regarding the epidemiology and pathogenesis of NMOSD, to reduce barriers to performing well-designed therapeutic trials, and to support postapproval studies of eventually approved therapeutics. Thus, the overarching goal of CIRCLES is to improve patient quality of life through improved diagnosis, relapse prevention, and eventual cures.38,–,40

The CIRCLES program enables unprecedented opportunities to accelerate breakthroughs in scientific understanding and clinical solutions for NMOSD. Key to the future applicability of CIRCLES will be increased precision in diagnosis and uniformity in the assessment and specification of distinct disease phenotypes. These advances hinge on greater consistency of serologic analysis regarding autoantibodies specific to disease phenotype and standardization in the definition and severity scoring of NMOSD relapses. As these advances are made, they will be incorporated into the definitions used by CIRCLES, attesting to the evolving nature of this research platform. CIRCLES remains an open resource to facilitate hypothesis generation and testing. Given the nature of the biospecimens being collected, CIRCLES enables studies ranging from genomics, transcriptomics, proteomics, and other molecular- and cellular-based research, in addition to clinical investigation.

Study funding

The CIRCLES project is supported by The Guthy-Jackson Charitable Foundation.

Disclosure

L.J. Cook is supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. J.W. Rose is supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research; he receives research funding from the National Multiple Sclerosis Society, Biogen, and NIH. J.S. Alvey, A.M. Jolley, R. Kuhn, B. Marron, M. Pederson, R. Enriquez, J. Yearley, and S. McKechnie are supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. M.H. Han served on the advisory committee of Novartis; received travel funding and/or speaker honoraria from the University of California, San Diego, and CMSC; consulted for Sanofi Genzyme; and received research support from The Guthy-Jackson Charitable Foundation and The Leducq Foundation. A.J. Tomczak is supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. M. Levy is on the scientific advisory boards of Asterias, Chugai, and Alexion; is on the editorial board of Multiple Sclerosis and Related Disorders; holds a patent for aquaporin-4 sequence that elicits pathogenic T cell response in animal model of neuromyelitis optica; has consulted for Guidepoint Global, Gerson-Lehrman Group, and Cowen Group; and received research support from Viropharma/Shire, Acorda, ApoPharma, Sanofi, Genzyme, Alnylam, Alexion, Terumo BCT, NIH/NINDS, and The Guthy-Jackson Charitable Foundation. M.A. Mealy and J. Coleman are supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. J.L. Bennett is on the editorial boards of the Journal of Neuro-ophthalmology, Multiple Sclerosis, and Neurology: Neuroimmunology & Neuroinflammation; holds a patent for compositions and methods for the treatment of neuromyelitis optica; has consulted for AbbVie, EMD Serono, Mallinckrodt Pharmaceuticals, Equillium, MedImmune, Chugai, Frequency Therapeutics, Genentech, Genzyme, and Clene Nanomedicine; and received research support from EMD Serono, Mallinckrodt, NIH, and The Guthy-Jackson Charitable Foundation. R. Johnson and M. Barnes-Garcia are supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. A.L. Traboulsee has the following competing financial interests: research funding from Biogen, Chugai, Novartis, Roche, and Sanofi Genzyme; consultancy honoraria from Biogen, Roche, Sanofi Genzyme, and Teva Neuroscience; and supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. R.L. Carruthers is Site Investigator for studies funded by Roche, Novartis, MedImmune, and EMD Serono; receives research support from Teva Innovation Canada, Roche Canada, Vancouver Coastal Health Research Institute; and is supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. R.L. Carruthers has received honoraria from Roche, EMD Serono, Sanofi, Biogen, Novartis, and Teva. L.E. Lee, J.L. Schubert, and K. McMullen were supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. I. Kister served on the scientific advisory boards of Biogen and Genentech and received research support from The Guthy-Jackson Charitable Foundation, National Multiple Sclerosis Society, Biogen, EMD Serono, Genentech, Genzyme, and Novartis. Z Rimler and A. Reid are supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. N.L. Sicotte is supported in part by the National Multiple Sclerosis Society, the Patient-Centered Outcomes Research Institute (PCORI), and The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. S.M. Planchon is supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. J.A. Cohen reports personal compensation for consulting for Alkermes, Biogen, Convelo, EMD Serono, ERT, Gossamer Bio, Novartis, and ProValuate, speaking for Mylan and Synthon, and serving as an editor of Multiple Sclerosis Journal, and was supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. D. Ivancic and J.L. Sedlak are supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. I.K. Sand receives research support from United States Department of Defense, the National Multiple Sclerosis Society, and The Guthy-Jackson Charitable Foundation. P. Repovic received travel funding and/or honoraria from Biogen, EMD Serono, Genzyme, and Genentech, consulting fees from Biogen, Novartis, Genentech, and EMD Serono, and research support from Genentech, National Multiple Sclerosis Society, and Consortium of MS Centers, and was supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. L. Amezcua has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme. She receives research funding from Biogen, MedDay, NMSS, NIH NINDS, California Community Foundation, and The Guthy-Jackson Charitable Foundation. A. Pruitt and E. Amundson are supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. T. Chitnis served on the clinical advisory boards of Novartis, Celgene, and Sanofi Genzyme; consulted for Biogen, Celgene, Novartis, and Sanofi Genzyme; received research support from Merck Serono, Verily, NIH, MNSS, Peabody Foundation, and Consortium for MS Centers; and was supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of the research. D.S. Mullin is supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. E.C. Klawiter has received consulting fees from Acorda Therapeutics, Atlas5d, Biogen Idec, EMD Serono, Genentech, and Shire and research support from Atlas5d, Biogen Idec, EMD Serono, and Roche and was supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. A.W. Russo is supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. C.S. Riley has participated in advisory boards and received honoraria from Novartis, Biogen Idec, Teva, Genentech, Roche, and Genzyme and was supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. K.B. Onomichi, L. Levine, K.E. Nelson, N.M. Nealon, and C. Engel are supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. M. Kruse-Hoyer reports no disclosures. M. Marcille, L. Tornes, A. Rumpf, A. Greer, M. Kenneally Behne, R.R. Rodriguez, D.W. Behne, D.W. Blackway, and B. Coords are supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. T.F. Blaschke is an advisor to The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. J. Sheard is supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. T.J. Smith is an advisor to The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. J.M. Behne is supported in part by The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. M.R. Yeaman is supported by research funding from the National Institutes of Health; U.S. Department of Defense; is Founder and Shareholder of NovaDigm Therapeutics, Inc.; is Founder and Shareholder of Metacin, Inc; and is Advisor to The Guthy-Jackson Charitable Foundation, which is a sponsor of this research. Go to Neurology.org/NN for full disclosures.

Acknowledgment

The authors recognize the efforts of the following individuals: Yanet Babcock, Alexandra Kocsik, J. Michael Dean, Colleen Farrell, Haojun Feng, Susan Filomena, Toni Ganaway, Samuel Glaisher, Rivka Green, Elizabeth Gonzales, Elaine Hsu, Catherine J. Johnson, Marlene Keymolen Ramirez, Gloria Rodriguez, Angela Stangorone, Ben W. Thrower, and Gabriella Tosto. The CIRCLES project team, including site PIs and coordinators, the DCC team, and The GJCF and its advisors are grateful to study participants, caregivers, and families who participated in this study. The CIRCLES project is supported by The Guthy-Jackson Charitable Foundation.

Appendix 1 Authors

Appendix 2 Coinvestigators

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by The Guthy-Jackson Charitable Foundation.

  • GJCF-ICC Coinvestigators are listed in Appendix 2.

  • Received February 21, 2019.
  • Accepted in final form May 17, 2019.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Akaishi T,
    2. Nakashima I,
    3. Sato DK,
    4. Takahashi T,
    5. Fujihara K
    . Neuromyelitis optica spectrum disorders. Neuroimaging Clin N Am 2017;27:251–265.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Marignier R,
    2. Cobo Calvo A,
    3. Vukusic S
    . Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol 2017;30:208–215.
    OpenUrl
  3. 3.↵
    1. Weinshenker BG,
    2. Wingerchuk DM
    . Neuromyelitis spectrum disorders. Mayo Clin Proc 2017;92:663–679.
    OpenUrl
  4. 4.↵
    1. Whittam D,
    2. Wilson M,
    3. Hamid S,
    4. Keir G,
    5. Bhojak M,
    6. Jacob A
    . What's new in neuromyelitis optica? A short review for the clinical neurologist. J Neurol 2017;264:2330–2344.
    OpenUrl
  5. 5.↵
    1. Flanagan EP,
    2. Cabre P,
    3. Weinshenker BG, et al
    . Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016;79:775–783.
    OpenUrl
  6. 6.↵
    1. Houzen H,
    2. Kondo K,
    3. Niino M, et al
    . Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology 2017;89:1995–2001.
    OpenUrl
  7. 7.↵
    1. Sepulveda M,
    2. Aldea M,
    3. Escudero D, et al
    . Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler 2017 Epub 2017 Oct 1.
  8. 8.↵
    1. Pandit L,
    2. Asgari N,
    3. Apiwattanakul M, et al
    . Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 2015;21:845–853.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Borisow N,
    2. Kleiter I,
    3. Gahlen A, et al
    . Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Mult Scler 2017;23:1092–1103.
    OpenUrl
  10. 10.↵
    1. Sepulveda M,
    2. Armangue T,
    3. Sola-Valls N, et al
    . Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 2016;3:e225. doi:10.1212/NXI.0000000000000225.
    OpenUrl
  11. 11.↵
    1. Kim HJ,
    2. Paul F,
    3. Lana-Peixoto MA, et al
    . MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84:1165–1173.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Paul F,
    2. Murphy O,
    3. Pardo S,
    4. Levy M
    . Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs 2018;27:265–271.
    OpenUrl
  13. 13.↵
    1. Trebst C,
    2. Jarius S,
    3. Berthele A, et al
    . Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1–16.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Wingerchuk DM,
    2. Banwell B,
    3. Bennett JL, et al
    . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–189.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Jarius S,
    2. Kleiter I,
    3. Ruprecht K, et al
    . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement—frequency, presentation and outcome. J Neuroinflammation 2016;13:281.
    OpenUrl
  16. 16.↵
    1. Jarius S,
    2. Ruprecht K,
    3. Kleiter I, et al
    . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13:280.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Jarius S,
    2. Ruprecht K,
    3. Kleiter I, et al
    . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016;13:279.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Kleiter I,
    2. Gahlen A,
    3. Borisow N, et al
    . Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016;79:206–216.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Mealy MA,
    2. Wingerchuk DM,
    3. Greenberg BM,
    4. Levy M
    . Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012;69:1176–1180.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Pache F,
    2. Zimmermann H,
    3. Mikolajczak J, et al
    . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 2016;13:282.
    OpenUrl
  21. 21.↵
    1. Collongues N,
    2. Marignier R,
    3. Zephir H, et al
    . Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010;74:736–742.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Jarius S,
    2. Ruprecht K,
    3. Wildemann B, et al
    . Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Ngo ST,
    2. Steyn FJ,
    3. McCombe PA
    . Gender differences in autoimmune disease. Front Neuroendocrinol 2014;35:347–369.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Tackley G,
    2. O'Brien F,
    3. Rocha J, et al
    . Neuromyelitis optica relapses: race and rate, immunosuppression and impairment. Mult Scler Relat Disord 2016;7:21–25.
    OpenUrl
  25. 25.↵
    1. ZhangBao J,
    2. Zhou L,
    3. Li X, et al
    . The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients. J Neuroimmunol 2017;302:49–55.
    OpenUrl
  26. 26.↵
    1. Wingerchuk DM,
    2. Lennon VA,
    3. Pittock SJ,
    4. Lucchinetti CF,
    5. Weinshenker BG
    . Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485–1489.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Asgari N,
    2. Lillevang ST,
    3. Skejoe HP,
    4. Falah M,
    5. Stenager E,
    6. Kyvik KO
    . A population-based study of neuromyelitis optica in Caucasians. Neurology 2011;76:1589–1595.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Jacob A,
    2. Panicker J,
    3. Lythgoe D, et al
    . The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 2013;260:2134–2137.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Cossburn M,
    2. Tackley G,
    3. Baker K, et al
    . The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 2012;19:655–659.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Cabre P,
    2. Gonzalez-Quevedo A,
    3. Lannuzel A, et al
    . Descriptive epidemiology of neuromyelitis optica in the Caribbean basin [in French]. Rev Neurol (Paris) 2009;165:676–683.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Pandit L,
    2. Kundapur R
    . Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 2014;20:1651–1653.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Mori M,
    2. Kuwabara S,
    3. Paul F
    . Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 2018;89:555–556.
    OpenUrlFREE Full Text
  33. 33.↵
    1. Spadaro M,
    2. Gerdes LA,
    3. Krumbholz M, et al
    . Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016;3:e257. doi:10.1212/NXI.0000000000000257.
    OpenUrl
  34. 34.↵
    1. Zamvil SS,
    2. Slavin AJ
    . Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015;2:e62. doi:10.1212/NXI.0000000000000062.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Reindl M,
    2. Rostasy K
    . MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm 2015;2:e60. doi:10.1212/NXI.0000000000000060.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Kremer S,
    2. Renard F,
    3. Achard S, et al
    . Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder. JAMA Neurol 2015;72:815–822.
    OpenUrl
  37. 37.↵
    1. Melamed E,
    2. Levy M,
    3. Waters PJ, et al
    . Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e134. doi:10.1212/NXI.0000000000000134.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Chavarro VS,
    2. Mealy MA,
    3. Simpson A, et al
    . Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2016;3:e286. doi:10.1212/NXI.0000000000000286.
    OpenUrlCrossRef
  39. 39.↵
    1. Penner IK,
    2. Paul F
    . Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol 2017;13:662–675.
    OpenUrl
  40. 40.↵
    1. Zhao S,
    2. Mutch K,
    3. Elsone L,
    4. Nurmikko T,
    5. Jacob A
    . Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Mult Scler 2014;20:1658–1661.
    OpenUrlCrossRefPubMed
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement